BiotechTube
Home/ImmunityBio/Richard (Rich) Adcock
R(

Richard (Rich) Adcock

President & Chief Executive Officer

ImmunityBio

Therapeutic Areas

Bladder CancerNon-Small Cell Lung CancerGlioblastomaLynch SyndromeNon-Hodgkin LymphomaOvarian CancerHIV

ImmunityBio Pipeline

DrugIndicationPhase
ANKTIVA® + BCGBCG-Unresponsive NMIBC CIS ± PapillaryApproved
ANKTIVA® + TislelizumabNon-Small Cell Lung Cancer (NSCLC)Phase 3
ANKTIVA® + PD-1 InhibitorCheckpoint Inhibitor-Refractory NSCLCPhase 2
aNK / PD-L1 t-haNK Cell TherapiesVarious Solid TumorsPhase 1/2
Therapeutic Cancer VaccinesVarious CancersPreclinical/Phase 1
ANKTIVA-based regimensHIVPhase 1/2

Leadership Team at ImmunityBio

DP
Dr. Patrick Soon-Shiong
Founder, Executive Chairman, Global Chief Scientific and Medical Officer
View full ImmunityBio profile